These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2884654)

  • 21. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G; Rogóz Z; Wieczorek A
    Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benzamides and classical neuroleptics: comparison of their actions using 6 apomorphine-induced effects.
    Puech AJ; Simon P; Boissier JR
    Eur J Pharmacol; 1978 Aug; 50(4):291-300. PubMed ID: 29758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological activity of picobenzide (3,5-dimethyl-N-(pyridin-4-ylmethyl)benzamide) analogues as potential antipsychotic agents.
    Gradillas A; López B; Braña MF; Sancho I; Pérez-García C; Alguacil LF
    Arzneimittelforschung; 2005; 55(12):725-9. PubMed ID: 16430025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine.
    Fray PJ; Sahakian BJ; Robbins TW; Koob GF; Iversen SD
    Psychopharmacology (Berl); 1980; 69(3):253-9. PubMed ID: 6774363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SKF 38393 and apomorphine modify locomotion and exploration in rats placed on a holeboard by separate actions at dopamine D-1 and D-2 receptors.
    Fletcher GH; Starr MS
    Eur J Pharmacol; 1985 Nov; 117(3):381-5. PubMed ID: 3878300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiation of apomorphine-induced stereotyped behaviour by acute treatment with dopamine depleting agents: a potential role for an increased stimulation of D1 dopamine receptors.
    Vasse M; Protais P
    Neuropharmacology; 1989 Sep; 28(9):931-9. PubMed ID: 2554186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic comparison of apomorphine-induced behavioral changes in two mouse strains with inherited differences in brain dopamine receptors.
    Seale TW; McLanahan K; Johnson P; Carney JM; Rennert OM
    Pharmacol Biochem Behav; 1984 Aug; 21(2):237-44. PubMed ID: 6541342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remoxipride, a specific D2 dopamine antagonist: an examination of its self-administration liability and its effects on d-amphetamine self-administration.
    Amit Z; Smith BR
    Pharmacol Biochem Behav; 1992 Jan; 41(1):259-61. PubMed ID: 1347174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential interaction of neuroleptics with apomorphine-induced behavior in rats as a function of changing levels of dopamine receptor stimulation.
    Megens AA; Hendrickx HM; Lavreysen H; Langlois X
    J Pharmacol Exp Ther; 2013 Dec; 347(3):681-96. PubMed ID: 24071734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of dopamine antagonists discriminating various behavioral responses and radioligand binding sites.
    Martres MP; Sokoloff P; Delandre M; Schwartz JC; Protais P; Costentin J
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Feb; 325(2):102-15. PubMed ID: 6144046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.
    Nadal R
    CNS Drug Rev; 2001; 7(3):265-82. PubMed ID: 11607043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apomorphine-induced locomotion and gnawing: evidence that the experimental design greatly influences gnawing while locomotion remains unchanged.
    Ljungberg T; Ungerstedt U
    Eur J Pharmacol; 1977 Nov; 46(2):147-51. PubMed ID: 563330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-opiate beta-endorphin fragments and dopamine--I. The neuroleptic-like gamma-endorphin fragments interfere with the behavioural effects elicited by small doses of apomorphine.
    Van Ree JM; Innemee H; Louwerens JW; Kahn RS; De Wied D
    Neuropharmacology; 1982 Nov; 21(11):1095-101. PubMed ID: 6184639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A critical assessment of behavioural test procedures used to analyse dopaminergic and antidopaminergic drugs.
    Nohria V
    Methods Find Exp Clin Pharmacol; 1983; 5(6):357-64. PubMed ID: 6137599
    [No Abstract]   [Full Text] [Related]  

  • 35. Antipsychotic substances and dopamine in the rat brain; behavioral studies reveal distinct dopamine receptor systems.
    Van Ree JM; Elands J; Király I; Wolterink G
    Eur J Pharmacol; 1989 Aug; 166(3):441-52. PubMed ID: 2572429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of apomorphine-induced gnawing in mice.
    Hedley LR; Wallach MB
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(1):47-56. PubMed ID: 6682986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the effects of the novel antipsychotic agent remoxipride on dopamine and noradrenaline turnover in the rat brain.
    Magnusson O; Fowler CJ
    Pharmacol Toxicol; 1989 Oct; 65(4):295-8. PubMed ID: 2573899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of remoxipride, a dopamine D-2 antagonist antipsychotic, on sleep-waking patterns and EEG activity in rats and rabbits.
    Ongini E; Bo P; Dionisotti S; Trampus M; Savoldi F
    Psychopharmacology (Berl); 1992; 107(2-3):236-42. PubMed ID: 1352054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the D1 receptor agonist SKF 38393 on some behavioural effects of apomorphine in rats.
    Zarkovsky AM; Cereska KS
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Apr; 339(4):383-6. PubMed ID: 2567965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yawning and suppression of exploration in amphetamine-treated rats, incompatibility with the autoreceptor hypothesis.
    Ståhle L; Ungerstedt U
    Psychopharmacology (Berl); 1989; 97(4):553-60. PubMed ID: 2567032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.